A selective nonpeptide endotheli n A (ETA) receptor antagonist, CI-1020, was administered to beagle dogs intravenously (iv) for 4 hours to 4 weeks. One animal/sex received CI-1020 at 1 mg/kg/hr intravenousl y for 4, 8, or 24 hours to investigate onset of arteriopathy. Control animals (1/sex) received the vehicle only. To determine reversibility of arteriopathy, 8 dogs/sex were given CI-1020 at 1 mg/kg/hr for 4 days. Two dogs/sex were sacri ced 1, 3, 8, and 29 days following cessation of infusion. Lesion developmen t with prolonged exposure was investigated in 1 male dog. It was given CI-1020 by iv bolus at 120 mg/kg/day for 4 weeks and Monastral blue dye was administered iv to facilitate localization of vascular lesions. Coronary blood ow was determined in 4 dogs infused with CI-1020 at 0.3, 3, and 30 mg/kg for one hour at each dose. Macroscopically, hemorrhage or blue discoloration of Monastral blue was noted in the extramural coronary arteries along the coronary groove and atrium. Histologically, the earliest coronary changes were noted in animals sacri ced after 24 hours of treatment and characterized by medial hemorrhage and necrosis with a few in ltrating neutrophils. In the reversibility study, incidence and severity of arteriopathy was dependen t on time of sacri ce following cessation of infusion. Acute necrotizing in ammation of arteries was present in all animals (n 4) on day 1 postinfusion, whereas on day 8 postinfusion, lesions characterized by medial small pockets of trapped red cells, cell debris, and adventitial thickening were seen in 1 dog/sex. By day 29 postinfusion, coronary arteries were similar to controls. In the dog given daily IV bolus injections of CI-1020 for 4 weeks, arterial in ammatory lesions varied from acute to chronic, although most lesions were considered chronic active. Monastral blue pigments were noted in the wall of most arteries with chronic or chronic active lesions. Acute lesions were similar to those noted in day 1 postinfusion of the reversibility study. Medial smooth muscle necrosis and/or brosis with mixed in ammatory cell in ltrates characterized chronic or chronic active lesions. Smooth muscle proliferation and migration into the intima were also noted. There were no signi cant changes in coronary blood ow, coronary vascular resistance, or mean arterial blood pressure following CI-1020 infusion for 3 hours. In the 24-hour infusion study, plasma endothelin 1 (ET-1) levels were mildly elevated (1.5-4 fold) during CI-1020 infusion when compared to either pretest or control values. These results indicate that administration of endothelin antagonist (CI-1020) to dogs was associated with development of coronary arteriopathy, which was completely resolved within 29 days following cessation of treatment. With prolonged (4-week) CI-1020 treatment, arterial lesions at varying stages of developmen t (acute, chronic active, chronic) were seen, suggesting that tolerance to treatment (up to 4 weeks) does not occur.
INTRODUCTION
Arteriopathy, primarily in dogs, is a serious complicating factor in toxicity studies with vasoactive compounds. Administration of various types of xenobiotics such as vasodilators (minoxidil, theobromine, hydrazine, and type III phosphodiesterase inhibitors), adenosine agonist, and adrenergic inotropic amines (isoproterenol, norepinephrine, dopamine, and dobutamine) are associated with arteriopathy in dogs (2, 4, 6, 8, 12, 13, 19) . Endothelin A receptor (ET A ) antagonist CI-1020 was shown to produce coronary arteriopathy in dogs following 4-day continuous intravenous (iv) infusion dogs at doses between 0.3 and 20 mg/kg/hr (25) . Two other reports (10, 22) showed similar ndings in dogs given ET A or a mixed (ET A/B ) endothelin receptor antagonist SB 209670 by continuous iv infusion for 3 to 14 days.
Endothelin (ET-1) is considered the most potent vasoconstrictor discovered to date (15) . There are two additional related peptides termed ET-2 and ET-3, and two distinct ET-receptor subtypes termed ET A (selective for ET-1) and ET B (nonselective with respect to isopeptides of the ET family). ET A receptors are abundant in cardiovascular tissue, while ET B receptors are abundant in noncardiovascular tissues including kidney, adrenal, and central nervous system (7, 15, 24) . CI-1020 (PD 156707); sodium 2-benzo [1, 3] dioxol-5-yl-4-(4-methoxyphenyl)-4-oxo-3-(3,4,5-trimethoxy-benzyl )-but-2-enoate; a highly potent and selective nonpeptide ET A receptor antagonist in vivo and in vitro (17) has been investigated for potential treatment of pulmonary hypertension (5) . CI-1020 binds to human ET A receptors with an approximately 800-fold higher af nity than to human ET B receptors, as observed in competition binding assays with recombinant human ET A and ET B receptors (17) .
The objectives of these studies were: 1) determine onset and characterize acute vascular injury following initiation of iv CI-1020 infusion; 2) to study reversibility of observed coronary arterial changes; and 3) to characterize vascular lesions with prolonged CI-1020 administration. In addition, a special study to measure coronary blood ow was performed in conscious dogs to determine if vasodilation was associated with development of vascular injury.
MATERIALS AND METHODS
Animals and Husbandry. For toxicology studies, male and female beagle dogs (Marshal Farms USA, Inc) were used and mongrel dogs were used for the coronary blood ow study. The animals were housed individually in a room with temperature and relative humidity maintained at 22 4 C and 30-70%, respectively, with a 12-hour light cycle. The animals were provided with water ad libitum and standard diet once daily (Purina Certi ed Canine Diet #5007, Ralston Purina Inc, St. Louis, MO). Animal care conformed to current guidelines in both the United States and Canada, and all procedures were reviewed and approved by an institutional animal care committee.
Compound Administration. For iv infusion, CI-1020 was dissolved in L-lysine (2 moles of L-lysine/mole of CI-1020) and 0.45% saline and administered using infusion pumps. Two weeks prior to initiation of dosing, animals were implanted with vascular access ports (VAP) and catheters using sterile surgical techniques. Surgical sites were lateral dorsal thorax for the VAP and the ventral neck for catheter insertion into the jugular vein. For coronary blood ow and arterial blood pressure study, 2 weeks prior to testing, mongrel male dogs were instrumented at sterile surgery with coronary ultrasonic ow probes (Transonic Systems, Inc, Ithaca, NY), arterial blood pressure catheters, and venous catheters. The catheters were constructed using PE 100 with an over sleeved tip of 0.030 0.065 Silastic. Only the Silastic portion of the catheters was introduced into the lumen of the vessels. During surgery, the arterial catheter was positioned in the descending thoracic aorta to enable measurement of arterial blood pressure, and the venous catheter was placed into the pulmonary artery to serve as a venous access site. The left circum ex coronary artery was isolated from surrounding tissues and the owprobe was placed around the artery to measure left circum ex coronary blood ow.
Intravenous Toxicology Studies.
Three studies were performed. The rst study was conducted to identify the time to induction of vascular lesions. Three dogs of each sex received CI-1020 at 1 mg/kg/hr (24 mg/kg/day). One dog of each sex was sacri ced at 4, 8, or 24 hours following initiation of infusion. Controls, 1 animal/sex, received vehicle only and were sacri ced at 24 hours. The second study was conducted to evaluate reversibility of vascular injury. Eight dogs of each sex were given CI-1020 by continuous iv infusion at 1 mg/kg/hr for 4 days. Two dogs/sex given CI-1020 were sacri ced 1, 3, 8, or 29 days following cessation of infusion. Vehicle control dogs, 2/sex, were sacri ced 1 and 29 days postinfusion. The selected dose of 1 mg/kg/hr was based on previous studies (25) that showed that this dose caused coronary arteriopathy with no signi cant clinical signs. The third study was conducted to characterize vascular lesions following prolonged drug exposure. In this study, one male dog was given CI-1020 by iv bolus at 60 mg/kg twice daily (120 mg/kg total daily dose) for 4 weeks. The dose for this study was selected based on a previous iv bolus infusion study (Parke-Davis Pharmaceutical Research Division, unpublishe d results) in dogs. In that study, no signi cant clinical signs were seen at doses 60 mg/kg. Emesis and diarrhea were seen at 80 mg/kg, and severe clinical signs including tremors, hyperreactivity, aggression, and panting were evident at 160 mg/kg. As such, 120 mg/kg/day was expected to be well-tolerated for 4-weeks. The dose of 120 mg/kg was split to lower the possibility of emesis. To better identify coronary arterial lesions and to grossly localize sites of coronary vascular damage, a marker dye (Monastral blue B) was administered on days 9 and 10 as a single bolus intravenous injection. Monastral blue (MB), 3% (w/v) suspension (Sigma-Aldrich Canada Ltd, Oakville, Ontario) was given at a volume of 2 ml/kg. The vehicle for Monastral blue B was 40% hydroxypropyl -b -cyclodextrin (Cerestar USA, Inc, Hammond, IN).
Coronary Blood Flow Study. Four male adult dogs were instrumented with coronary ow probes. Following a 1-hour baseline period, CI-1020 was infused at 0.3, 3.0, and 30.0 mg/ kg for 1 hour at each dose. CI-1020 infusion was followed by adenosine infusion (100 l g/kg/min) for 10 minutes. The adenosine infusion was used to determine if a known coronary vasodilator would elicit reductions in coronary vascular resistance above and beyond that produced by CI-1020. A repeated-measures analysis of variance (ANOVA) was used to test for signi cant variations in the data. A p value < 0.05 was accepted as a signi cant change from baseline values. Clinical Observations. Animals were observed for clinical sings of toxicity and systemic effects. In the toxicology studies, food consumption was assessed daily. Dogs were weighed prior to study start, weekly, and at termination. Clinical and ophthalmic examinations were performed pretest and at termination. Blood pressure and/or electrocardiograms were done predose and within approximately 1 hour of the end of intravenous infusion.
Clinical Laboratory Analyses. In the reversibility study, blood was collected from each dog pretest, at the end of dosing, at 24 hours postinfusion, and at subsequent termination time-points 3, 8, and 29 days postinfusion. Clinical pathology parameters evaluated in blood or serum included red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin, platelet count, white blood cell count (total and differential), urea nitrogen (BUN), creatinine, alanine and aspartate aminotransferase (ALT, AST), cholesterol, triglyceride, total protein, albumin, globulin, gamma glutamyl transferase, lactate dehydrogenase (total), alpha hydroxybutyrate dehydrogenase, 5 -nucleotidase, creatine kinase (CK), and C reactive protein.
Plasma CI-1020 and Endothelin-1 Determinations. In the arteriopathy onset study, heparinized blood samples were collected pretest and at the end of the speci ed dosing periods for determination of plasma CI-1020 concentration. Similar samples were taken using EDTA as anticoagulant for endothelin-1 determinations. In the arteriopathy reversibility study, heparinized blood samples were collected at the end of the 4-day dosing period, and 24 hours postinfusion for plasma CI-1020 determinations.
Pathology. Dogs were euthanatized with iv overdose of sodium pentobarbital. Complete necropsies were done on all dogs in the toxicology studies. In order to provide optimal xation of the heart and the coronary vessels, the heart was removed along with a 3-5 cm segment of attached aorta. Hearts were perfused-xed ex vivo. The aorta was cannulated and perfused with Ringer's solution for 1-2 minutes followed by perfusion with 10% buffered formalin xative for an additional 5-10 minutes. For the arteriopathy onset study, a peristaltic pump was used to deliver the perfusate at a ow rate of 55 mL/minute. For all other studies, a manual pressurized pump (18) was used to deliver the perfusate at 30 mm Hg. Three cross-section samples each from the circum ex branch, left interventricular, and right coronary arteries were collected. The rst circum ex branch sample was taken about 0.5 cm from the left coronary artery. The remaining samples were about 1 to 2 cm apart. The sampling procedure for the right coronary and interventricular arteries was similar to those noted for the circum ex artery. Sections from the respective ventricle, 0.5 cm long, and atrium, 1-2 cm long, were also included with the extramural coronary artery samples. All heart sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome (3) .
Immunohistochemistry. Localization of actin in representative heart sections from the 4-day intravenous reversibility study and from the 4-week study was done using mouse antihuman muscle actin antibodies (clone HH35, DAKO Corp, Santa Barbara, CA). Reactions were visualized with an avidin-biotin-alkaline phosphatase kit (Vectastain ABC-AP kit, Vector Laboratories Inc, Burlingame, CA) using Vector Red as the chromogen (Vector Laboratories Inc, Burlingame, CA). The sections were counterstained with Verhoeff hematoxylin (3).
RESULTS
The following includes only drug-related results; if not reported, results were comparable to concurrent or historical controls or were not considered drug related.
Arteriopathy Onset Study
Petechial epicardial ventricular hemorrhages were noted at necropsy of the male sacri ced following 24 hours of CI-1020 treatment. Histologically, no arteriopathy was seen at these areas. The earliest vascular in ammatory changes were noted in both male and female animals sacri ced after 24 hours of CI-1020 treatment. Arterial lesions varied from presence of hyaline globules and red cells in the media to overt hemorrhage, cell debris and smooth muscle necrosis of the media (Figure 1) . A few neutrophils were also noted in some vessels.
Arteriopathy Reversibility Study
There were no gross changes. On day 1 postinfusion, arteriopathy was of variable severity (minimal to marked), acute, and affected all animals. Arterial lesions were noted in the left and right extramural coronary arteries as well as the interventricular coronary arteries. Minimal changes were characterized by focal medial necrosis and hemorrhage with limited neutrophilic in ltrates in the media and adventitia. Marked lesions were noted in 1 male, involved medium and small arteries, and were characterized by segmental medial necrosis and hemorrhage with mixed in ammatory cell in ltrates in the intima, media and adventitia. Fibrin was also noted in the media and adventitia. Perivascular venules were prominent with hypertrophic endothelium. There was a loss of actin staining in media ( Figure 2 ) corresponding to areas of smooth muscle necrosis with disruption of the internal elastic lamina in some affected arteries.
On day 3 postinfusion, arteriopathy was minimal to mild, subacute in nature, and affected left and right coronary arteries of all animals. The lesion was less acute compared to day 1, however medial hemorrhage and necrosis were still present. In some arteries, islands of trapped red cells were seen in the media without appreciable smooth muscle necrosis. Neutrophilic in ltrates were replaced by mononuclear cell in ltrates (Figure 3 ). Perivascular granulation tissue was noted in a few arteries.
On day 8 postinfusion, arteriopathy was noted in 1 male and 1 female and was minimal in severity. The lesion was characterized by presence of small pockets of trapped red cells ( Figure 4 ) and necrotic cell debris in the media, and thickening of the adventitia. Adventitial thickening was primarily due to granulation tissue, although mononuclear cell in ltrates were also noted. The second male had adventitial thickening of several arterioles while the second female was unremarkable. Actin staining of smooth muscle was normal and no disruption of internal elastic lamina was noted. On day 29 postinfusion, no remarkable changes were noted and coronary arteries were similar to controls.
Four-Week IV Bolus Study
CI-1020-related changes were noted grossly in the extramural coronary arteries. Areas of blue discoloration (secondary to MB leakage) or hemorrhage were noted bilaterally in the coronary groove along the coronary arteries and atrium ( Figure 5) . Histologically, bilateral multifocal extramural coronary arteriopathy was noted. Affected arteries varied in size from arterioles to large muscular arteries. The age of the lesion varied from acute to chronic or chronic active, although most lesions were characterized as chronic active. MB pigments were noted in the wall of most arteries of chronic or chronic active lesions. Acute arterial changes were characterized by medial brinoid necrosis and hemorrhage with mixed in ammatory cell in ltrates in the adventitia ( Figure 6 ). In chronic active lesions, arterial changes were characterized by intimal thickening due to in ammatory cell in ltrates and/or brosis with smooth muscle proliferation. Vascular smooth muscle necrosis, hemorrhage, brosis, and/or mixed cell inltrates (Figure 7) with neovascularization were noted in the thickened media. Adventitial thickening was due to mixed cell in ltrates and/or brosis. Chronic arterial changes were characterized by minimal to mild brosis or smooth muscle proliferation/migration in the intima (Figure 8) , with no or minimal medial changes. Fibrosis of the adventitia was also seen. The media of many affected arteries contained MB pigments. Some healed arteries were indistinguishabl e from normal arteries except for the presence of MB pigments in the media (Figure 9 ). No changes were noted in the intramural coronary arteries. Marked neutrophilic in ltrates were noted in the coronary groove in areas of arterial damage. Arteriopathy was also noted in a thyroid artery and in several small arteries in the thoracic cavity. The media of several affected arteries contained MB pigments.
Coronary Blood Flow Study
There were no signi cant hemodynamic effects associated with CI-1020 infusion. As shown in Figure 10 , coronary blood ow was similar to baseline following escalating CI-1020 infusion at doses of 0.3, 3.0, and 30.0 mg/kg. Baseline coronary blood ow averaged 18 0.2 mL/min, whereas coronary blood ow averaged 20 0.2, 19 0.3, and 20 0.2 mL/min following CI-1020 doses of 0.3, 3.0, and 30.0 mg/kg, respectively. Infusion of the reference agent adenosine (100 l g/kg over 10 minutes) signi cantly ( p < 0.001) increased coronary blood ow to 48 5 mL/min. Similar ndings were obtained when coronary blood ow was corrected for changes in heart rate or the rate pressure product. Similarly, coronary vascular resistance (CVR) was not significantly altered during CI-1020 infusion. Baseline CVR measured 7.07 0.13 mm Hg/mL/min. CVR was slightly reduced (no statistical signi cance) to 6.10 0.1, 6.26 0.1, and 6.30 0.09 mm Hg/mL/min following escalating CI-1020 doses of 0.3, 3.0, and 30.0 mg/kg, respectively. Infusion of adenosine (100 l g/kg/10 minutes) produced a highly signi cant reduction in coronary vascular resistance averaging 3.17 0.42 mm Hg/mL/min ( p < 0.001). Mean arterial blood pressure (MABP) remained stable throughout the study. Baseline MABP averaged 101 1 mm Hg and varied from 108 1 to 103 1 mm Hg during infusions of CI-1020, adenosine, and the recovery period. Adenosine infusion was accompanied by a statistically signi cant ( p < 0.001) increase in mean heart rate (133 2 beats/min.) relative to baseline (97 1 beats/min). Heart rate following escalating CI-1020 infusion at 0.3, 3.0, and 30.0 mg/kg was similar to baseline and ranged from 99 1 to 104 1 beats/min.
Plasma CI-1020 Concentration
In the arteriopathy onset study (24-hour infusion), plasma CI-1020 concentrations were below limit of quantitation for males at 4 and 8 hours post initiation of iv infusion. Plasma concentrations in females increased with time (0.498, 0.86, and 1.40 l g/ml at 4, 8, and 24 hours, respectively). Plasma CI-1020 concentrations were similar in the male (1.21 l g/ml) and female (1.40 l g/ml) infused for 24 hours.
In the reversibility study, immediately following the 4-day continuous infusion, mean plasma concentrations of CI-1020 were higher in male dogs (1.33 0.76 l g/mL) than in females (0.783 0.664 l g/mL). Mean plasma CI-1020 concentrations were below limit of quantitation (BLQ) of 0.01 l g/mL in most dogs by 24 hours after infusion.
Endothelin-1 Levels
In the arteriopathy onset study (24-hour infusion), plasma ET-1 levels were higher after CI-1020 infusion when compared to pretest values or to controls. In dogs infused for 24 hours, ET-1 levels were about 2-to 4-fold higher than controls ( Table 1 ). In the reversibility study, immediately following the 4-day continuous infusion, mean ET-1 levels were higher in CI-1020-treated animals when compared to pretest values or to controls ( Table 2 ). By 24 hours post-CI-1020 infusion, mean ET-1 levels were lower than those recorded pretest.
DISCUSSION Administration of CI-1020 resulted in medial smooth muscle necrosis and hemorrhage of extramural coronary arteries as early as 24 hours of continuous iv infusion of CI-1020. These acute arterial lesions were similar to those described at 24 hours following oral administration of adenosine agonist CI-1047 (14) and a phosphodiesterase III inhibitor (SK&F 95654) (9) . Minimal microscopic coronary arterial lesions were also reported in dogs infused for 14 or 24 hours with a mixed (ET A/ B ) endothelin antagonist, SB 209670 (10) . The failure to induce arterial changes earlier than 24 hours correlated with low or undetectable CI-1020 plasma levels, which have not reached steady state, after 4 to 8 hours of infusion. This study con rms our hypothesis and others (22) that dogs are uniquely sensitive to development of coronary arterial injury. This hypothesis is also supported by the fact that CI-1020-induced coronary vascular injury in monkeys was not seen earlier than 2 weeks of continuous intravenous infusion (1).
In the reversibility study, as expected, the most severe changes were seen on the rst day following the cessation of CI-1020 infusion. Healing of injured vessels was demonstrated by reduction in severity and incidence of arterial lesions at subsequent time-points. By day 3 postinfusion, only the severity of lesions decreased, while on day 8 postinfusion, both incidence and severity were decreased. The loss of actin staining at sites of vascular injury on day 1 postinfusion is consistent with previous reports (23) , which showed loss of a -smooth muscle actin expression after arterial injury (26) . Medial smooth muscle cells have a high degree of plasticity and are able to shift from a differentiated contractile phenotype to a less differentiated synthetic phenotype and back again (23) . The cytoskeletal pro le of these cells is modi ed with shifts from smooth muscle a -actin to nonmuscle b -actin, from smooth muscle myosin to nonmuscle myosin and from desmin to vimentin (23) . Rapid regeneration of medial smooth muscle after cessation of treatment was demonstrated by positive actin staining in target vessels by day 8 postinfusion. By day 29 postinfusion, coronary vessels were indistinguishable from controls. In contrast, vascular injury in monkeys given CI-1020 was followed by medial brosis and limited medial smooth muscle regeneration (1) . Adventitial granulation tissue/ brosis noted at earlier time-points had also regressed by day 29. Repair of internal elastic lamina appeared complete by day 29. These ndings are in agreement with previous reports that indicated that repair/development of internal elastic lamina in arteries of dogs is more ef cient than that seen in humans (20, 21) .
In dogs treated chronically with CI-1020, intimal thickening and presence of smooth muscle cells in the intima were purely hyperplastic. The migration of vascular smooth muscle cell (VSMC) in response to injury requires a switch in genes activation. Genetic switching and phenotypic modulation result in altered intracellular proteins and are a prerequisite for VSMC migration and proliferation. The key stimuli for intimal hyperplasia are injury, in ammation, and increased wall stress (16) . The presence of MB pigment in several arteries in the thoracic cavity including thyroid arteries was indicative of drug-induced vascular injury and resolution. These ndings are consistent with previous CI-1020 studies, in which arteriopathy was noted in multiple tissues including meninges, urinary bladder, uterus, epididymis, and gastrointestinal tract (25) . Although there is apparent propensity for coronary vascular injury, involvement of arteries other than coronary arteries with CI-1020 is indicative of systemic effects consistent with those seen following administration of other vasoactive compounds (14) . The presence of MB pigment in relatively normal arteries with no disruption of the internal elastic membrane indicates the resolution of mild arterial injury with continuous treatment.
Coronary blood ow did not change in this study in dogs given escalating doses of CI-1020 for up to 3 hours. The absence of changes in coronary blood ow may be related to the short duration of this study. Previous studies (10, 11, 22) with endothelin antagonists (ET A or ET A/ B ) have shown treatment-related vasodilation of coronary arteries as early as 3 hours posttreatment and minor but sustained decreases in mean arterial blood pressure in with prolonged (5-day) treatment.
Vascular lesions seen following daily dosing with CI-1020 for 1 month were different from those noted after 1 or 4 days of treatment. In the acute studies, affected arteries were at a similar stage of acute injury, whereas, after 4 weeks of dosing, affected arteries were either acutely injured, completely repaired, or at subchronic in ammatory stage. These ndings are indicative of ongoing/persistent vascular injury and repair with prolonged CI-1020 treatment and are contrary to a previous study with a different vasoactive compound, Minoxidil (12) . Minoxidil-induced vascular lesions in the dog resolve with continued treatment: at 30 days, arterial lesions were characterized by perivascular brosis, medial distortion, and minimal intimal thickening. Additional chronic studies in larger numbers of animals are required to fully characterize the long-term cardiovascular effects of endothelin receptor antagonists in dogs.
